SOURCE: Amarillo Biosciences, Inc.

February 12, 2007 11:29 ET

Amarillo Biosciences Announces the Publication of Influenza Data

AMARILLO, TX -- (MARKET WIRE) -- February 12, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that the publication of data on the use of oral interferon for influenza is now available online in the Biochemical & Biophysical Research Communications (BBRC). These data indicate that oral interferon is life saving to treated mice given an otherwise fatal infection. These mice data are important because the mouse model is used by government laboratories to evaluate antivirals for testing in humans. The principal author of the online article in BBRC is Dr. Manfred Beilharz, Head, Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, M502, The University of Western Australia, Western Australia, 6009.

The Company is generating animal and human data in an effort to motivate government decision makers to consider the use of oral interferon in the management of pandemic influenza. As an alternative to other antivirals, the Company believes oral interferon fits one of the treatment priorities outlined by the National Strategies for Pandemic Influenza (Homeland Security), May 2006.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    e-mail: Email Contact
    Tel: 800-477-7570; 212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    e-mail: Email Contact
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301